The purpose of this study was to determine the frequencies of hereditary and familial breast cancers among Lower Silesian women. The questionnaires, dealing with cancer episodes in first-and second-degree relatives, were sent to 5,000 females, who were diagnosed with breast cancer between 1984 and 2005. Twenty-five percent of the questionnaires were completed and returned. Their analysis and further counseling revealed that 24.9% of the responders met the criteria for familial breast cancer (FBC), including 10.5% definitive cases. Mutations in BRCA1 were detected in 32.5% and 1.9% of patients with definitive and suspected FBC, respectively. They all represented three of the abnormalities of the BRCA1 gene: 300T/G, 4153delA and 5382insC. No mutations of BRCA2 were found in material studied. Although a fraction of FBCs identified in our study was similar to those described in other European countries and in the United States, the percentages of genetic mutations seen on routine tests were relatively low. Consequently, the standardized analysis of oncological pedigree seems to be a more valuable diagnostic tool if patients with familial aggregations of breast cancer are targeted in a prophylactic context only.
Introduction
The terms "hereditary breast cancer" and "familial breast cancer" are frequently incorrectly used as synonyms. Hereditary cancer is associated with known or suspected highpenetrance gene mutation. Two high-penetrance genes, BRCA1 and BRCA2, whose mutations are responsible for breast cancer have been identified to date [1] [2] [3] . It is estimated that the inheritance of those mutations is responsible for 5% to 10% of breast cancers diagnosed [4] .
Familial breast cancer (FBC) on the other hand refers to clusters of breast malignancies in a given family that do not appear to result from chance alone but still do not fit the stricter criteria for inherited breast cancer. According to various authors, the frequency of FBC varies from 20% to 30% in all cases registered [5] [6] [7] [8] .
Identification of patients susceptible to breast cancer is crucial in the context of a widely understood prophylaxis. Such prophylaxis should be oriented mostly toward reduced exposure to known risk factors and regular mammographic testing. Moreover, there are studies indicating that prophylactic mastectomy, oopheroctomy and even preventive tamoxifen administration reduce the risk of developing breast cancer [9] . Recent advances in clinical genetics give the possibility of testing for high-penetrance gene mutations. Familial susceptibility to cancer might in turn be suspected on the basis of oncological pedigree. Certain criteria, described by the "one-two-three" rule are useful to identify the familial aggregation of various malignancies. If at least three family members have cancer, including at least two malignancies in first-degree relatives, among which at least one was diagnosed before the age of 50, familial aggregation is confirmed and the risk of further oncological episodes is significantly elevated [10] .
The Lower Silesian province was created in 1999 as the result of territorial realignments in Poland. It is located in the south-west of the country (Fig. 1 ) and has 2,893,055 inhabitants, including 1,503,734 women. Compared to the other regions of Poland, the incidence of breast cancer in the Lower Silesian province is higher with a continually increasing tendency noted during recent decades [11] . Consequently, extensive prophylactic actions, including the identification of high-risk families, have become of major importance. Accordingly, the purpose of this study was to determine the frequencies of hereditary and familial breast cancers among Lower Silesian women.
Statistical methods and experimental procedures
The study was performed between 1998 and 2005 as part of the Oncological Genetic Counseling Program -a prophylactic project carried out by the Health Division of the Municipality of Wroclaw and Specialist Clinic ONKOMED in Wroclaw. The main goal of the program initiated in 1998 was to arrange and subsequently constantly update a cancer family data base as well as give oncological counseling and care to the families registered.
Breast cancer (C50) among Lower Silesian women was identified on the basis of 1984-2005 data from the Lower Silesian Cancer Registry [11] . Subsequently patients identified were sent a questionnaire dealing with cancer episodes in their first-and second-degree relatives (Fig. 2) . It was voluntary to fill in the form and send it back and all the procedures of data collection were in accordance with Polish law on the protection of personal data [12] .
Identified by a preliminary analysis of the questionnaire data, patients suspected of FBC were invited to the clinic for further counseling and examination. Women who did not meet the criteria of familial aggregation were informed of that fact via surface mail.
During the oncological consultation of patients suspected of FBC, the questionnaire data were verified and an oncological pedigree was completed. The data were analyzed on the basis of criteria summarized in Table 1 . Table 1 Criteria of definitive and suspected familial breast cancer (FBC) used in the study.
Definitive FBC Suspected FBC
At least three related females affected with breast or ovarian cancer, including one female diagnosed with one of the aforementioned cancers before the age of 50
One relative affected with one of the following: 1) breast cancer diagnosed before the age of 35, 2) breast and ovarian cancer, 3) bilateral breast cancer before the age of 50, 4) breast cancer (male)
Upon agreement, blood for genetic testing was obtained from patients with a definitive or suspected diagnosis of any BRCA1/2-related hereditary syndromes. Genetic testing for these gene mutations was kindly provided by the Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland. Genomic DNA was extracted from peripheral blood leukocytes according to Lahiri and Nurnberger [13] . The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations by means of SSCP followed by the direct sequencing of variants. The primers used for PCR amplification of BRCA1 and BRCA2 genes have been described in the Breast Cancer Information Core (BIC) database and by Friedman et al. [14] , respectively. Samples were sequenced with the use of fluorescently labeled dideoxy-chain terminators [15] from the ABI Prism Kit (PE Biosystems), in a model 373 automated DNA sequencer (PE Biosystems).
Results
The questionnaires were sent to 5,000 (HOC, n=5, 3 .8%); and 5) Li-Fraumeni syndrome (n=2, 1.5%).
Among the 180 suspected cases, we have diagnosed as follows: 1) HBC (n=129, 71.7%); 2) HBOC (n=29, 16.1%); 3) Lynch II syndrome (n=17, 9.4%); 4) HOC (n=2, 1.1%); 5) Lynch I syndrome (n=2, 1.1%); and 6) Li-Fraumeni syndrome (n=1, 0.6%).
Blood samples from 280 (90.0%) of 311 FBC patients (subjects with Lynch I/II and Li-Fraumeni syndromes were excluded) were screened for BRCA1/2 mutations. Mutations were detected in 39 (32.5%) and 3 (1.9%) cases with definitive and suspected FBC, respectively. They all represented three of the abnormalities of the BRCA1 gene: 300T/G, 4153delA and 5382insC. Their detailed distribution in patients with definitive and suspected cases of FBC is presented in Tables 2 and 3 , respectively. No mutations of BRCA2 were found in material studied. 
Discussion
We have identified FBC in about 25% of the breast cancer patients queried, which fraction is similar to those described in other European countries and in the United States [5] [6] [7] [8] .
Three mutations of the BRCA1 gene that we have detected in patients with definitive or suspected FBC are known as founder mutations in the Polish population [16] . According to a Polish nation-wide study these mutations occur in 66% of breast cancer families and in 63% of ovary-breast cancer families [17] . Although we have used the same molecular technique as previously described [16, 17] , BRCA1 mutations were found in 32.5% and 1.9% of patients with definitive or suspected FBC, respectively. Also the results of other regional studies suggest that the prevalence of BRCA1 mutations in Polish high-risk breast/ovarian cancer families (at least three related females affected) is variable -from more than 50% in Central Poland to about 15% in the Pomerania-Kujawy region [18] [19] [20] [21] . Hence, the percentage of mutations we have detected in patients with definitive FBC (identified by the criteria similar to the ones considered by [16] [17] [18] [19] [20] [21] ) fit within the aforementioned range. Different histories and ethnic compositions of various regions of Poland seem to be the main reason for the aforementioned geographic variability in the frequencies of BRCA1 mutations. Incorporation of Lower Silesia into Poland after World War II forced the emigration of a German autochthonic population, which was replaced by immigrants, mostly from former eastern regions of Poland. Consequently, founder mutations in the BRCA1 gene, prevalent in Central Poland, might still not be fully established, and consequently are less frequent in the Lower Silesian population. Similar historical and ethnical backgrounds might be related to the already mentioned low penetration of BRCA1 mutations in the Pomerania-Kujawy region [19] .
Qualitative distribution of BRCA1 mutations in Poland is, however, less regionspecific. Both in our study and in the other experiments cited [16] [17] [18] [19] [20] [21] 5382insC and 300T/G mutations were the most frequently detected.
A serious limitation of our study might be the fact that the completed and returned questionnaires were obtained from only 25% of breast cancer patients invited to the program. Consequently, the material analyzed may not be representative enough for the entire Lower Silesian population.
On the other hand, it may be assumed that breast patients with family histories of carcinomas were the ones who predominantly participated in our study. Following that assumption, the percentage of cancer patients identified as predisposed to familial aggregation in our study would be even overestimated. Nevertheless, the percentage of BRCA1 mutation carriers should then be expected to be higher than what is described in the literature. Since, as already mentioned, the incidence of breast cancer among Lower Silesian women is one of the highest in Poland [11] , the population analyzed, despite the low fraction of questionnaires sent back, was sufficiently representative.
Consequently, the low percentage of BRCA1 mutations and the lack of BRCA2 abnormalities identified in our study should also be discussed in the context of other altered breast cancer susceptibility genes rather than in relation to the sample representation itself. Indeed, literature data suggest that the role of BRCA1/2 in breast cancer inheritance gradually decreases along with advances in clinical genetics and the identification of "new" susceptibility genes. It is currently estimated that only 15% to 20% of the excess familial risk of breast cancer is due to mutations in BRCA1/2 [22] [23] [24] [25] . Moreover, recent findings suggest that several low-penetrance genes might be involved in hereditary breast cancer pathogenesis [25] [26] [27] .
Consequently, reliable genetic testing of individual patients becomes a complicated -and expensive -event. Concluding, the standardized analysis of oncological pedigree is sufficient if patients with familial aggregations of breast cancer are targeted in a prophylactic context only. Detailed testing for mutations in susceptibility genes is, however, indicated as an additional procedure, if the diagnosis of any of the familial syndromes suggests that further therapeutic procedures should be undertaken, as for instance the bilateral mastectomy in a subject with unilateral breast malignancy. Genetic testing is also advisable in patients with small families or limited knowledge about their relatives as well as in individuals whose parents and/or siblings died at an early age without acquiring cancer [28] .
Finally, not only physicians but also their patients should be aware of the diagnostic role of the oncological pedigree. The low percentage of questionnaire responses again proved that for various reasons patients are not interested in participating in that form of inquiry. It is plausible that relatively low health awareness as well as the time necessary to fill in and send back the questionnaire were the main factors responsible for the low percentage of patients participating in the program. It is characteristic, however, that all of women with familial aggregation of breast cancer, who were diagnosed on the basis of oncological pedigree, accepted screening for susceptibility gene mutations. Women's acceptance of such genetic testing was previously proved by several studies both in Poland and in other countries [29, 30] .
